Interferon beta 1a treatment induces the presence of autoreactive antibodies (ARAB) in patients with relapsing–remitting multiple sclerosis (RRMS)

Authors :: Christiana Kaliouli
Ioannis Markakis
Emmanouil Karamouzos
Chrysostomos Papastergios
G. Gekas
Pappa Eleni
Source :: Journal of Neuroimmunology. 275:167
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: biology
business.industry
Multiple sclerosis
Immunology
Interferon beta-1a
medicine.disease
Neurology
Relapsing remitting
biology.protein
Immunology and Allergy
Medicine
In patient
Neurology (clinical)
Antibody
business
medicine.drug

Full Text Access

Tools